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Abstract: The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small 
molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase. The current second generation 
of FDA-approved ABL tyrosine kinase inhibitors, dasatinib and nilotinib, are more potent inhibitors of BCR-ABL1 kinase in vitro. 
  Originally approved for the treatment of patients who were refractory to or intolerant of imatinib, dasatinib and nilotinib are now also 
FDA approved in the first-line setting. The choice of tyrosine kinase inhibitor (ie, standard or high dose imatinib, dasatinib, nilotinib) to 
use for initial therapy in chronic-phase CML (CML-CP) will not always be obvious. Therapy selection will depend on both clinical and 
molecular factors, which we will discuss in this review.
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Introduction
Chronic myelogenous leukemia (CML) is a relatively 
rare  disease,  with  an  estimated  4,000–5,000  new 
cases being diagnosed annually in the United States.1 
Nevertheless it has repeatedly served as a “keyhole” 
disease,  providing  insights  that  have    dramatically 
affected the broad fields of   oncology, cell biology, 
and molecular biology. The   sensitivity of CML to the 
tyrosine kinase inhibitor (TKI)   imatinib is certainly 
one of the most dramatic features of the disease. Ima-
tinib is now a well-known entity with obvious, pro-
found activity against CML, and the traditional dose 
(400 mg daily) has been the standard initial treatment 
for this disease. Its therapeutic benefits have also been 
extended to gastrointestinal stromal tumors,2 dermato-
fibrosarcoma protuberans,3 systemic mastocytosis,4,5 
and hypereosinophilic syndrome.6 These entities also 
express mutant kinases that are sensitive to the inhibi-
tory effects of imatinib.
While the vast majority of CML subjects benefit 
from imatinib therapy, it is also obvious that a sub-
stantial minority of patients with CML fail to benefit 
fully from this agent due to toxicity, lack of efficacy, 
or poor compliance. And there is no evidence that 
most patients with CML are being cured. Thus, at the 
end of the first decade of use of TKIs, it is appropriate 
to ask whether the treatment of CML can be further 
optimized. New therapies are available, as well as 
new insights into stem cell biology, kinase biochem-
istry, and medicinal chemistry. Further the validation 
of cytogenetic and molecular surrogate markers for 
efficacy assessment allows for improved efficiency in 
the identification of improved treatments. This review 
will focus on the application of newer agents to the 
initial treatment of chronic phase (CP) CML.
Imatinib for First-Line Therapy of cMI: 
proof of concept for TKIs
CML was the first cancer to be associated with a spe-
cific genetic anomaly, the Philadelphia chromosome. 
Molecular characterization of this aberrant chromo-
some  fragment  identified  the  t(9;22)  translocation 
that  produces  the  BCR-ABL1  chimeric  tyrosine 
kinase. The BCR-ABL1 kinase is both necessary and 
sufficient to produce CML-CP, unlike most malignan-
cies that require multiple genetic mutations to pro-
duce a fully transformed phenotype. This remarkable 
dependency on a specific, mutant protein has allowed 
CML to be the ideal “proof of concept” experiment 
to demonstrate the efficacy of small molecule kinase 
inhibitors. The introduction of imatinib for CML treat-
ment in 2001 has been a seminal event in the field of 
molecular oncology, and has provided dramatic ben-
efit to CML patients.
The  pivotal  phase  III  International  Randomized 
Study  of  Interferon  and  STI571  (IRIS)  trial  com-
pared the combination of recombinant interferon alfa 
and low-dose cytarabine to imatinib. After a median 
  follow-up of 19 months, the estimated rate of a major 
cytogenetic  response  (MCyR)  was  87.1%  in  the 
imatinib group and 34.7% in the group given inter-
feron alfa and cytarabine (P , 0.001). The estimated 
rates of complete cytogenetic response (CCyR) were 
76.2% and 14.5%, respectively (P , 0.001).2 At eight 
years of treatment, imatinib continues to demonstrate 
both efficacy and safety for the 304 (55%) patients 
remaining  on  study  treatment.8  Estimated  event-
free survival (EFS) at 8 years was 81% and freedom 
from progression to accelerated-phase or blast cri-
sis (AP/BC) was 92%. The rate of major molecular 
response (MMR) increased from 24% at six months 
and 39% at 12 months, to a “best observed” MMR of 
86% at 8 years. Estimated overall survival (OS) was 
85% at 8 years. These data suggest that for patients 
who initially respond to imatinib, responses can be 
maintained on long-term therapy, with a low side-
effect profile. These studies have established imatinib 
(400 mg daily) as the standard therapy for CML.
Because of the dramatic clinical effects of imatinib, 
coupled with a high proportion of cytogenetic and 
molecular responses, and the marked improvement in 
overall survival for CML patients,9,10 investigators are 
beginning to ask whether CML can be cured by TKIs. 
The initial results from the Stop Imatinib (STIM) trial 
have been presented recently.11 This trial documents 
the persistence of molecular remission after stopping 
imatinib, in subjects who had achieved a complete 
molecular response (CMR) lasting at least 2 years. 
At 12 months after imatinib withdrawal, 59% of sub-
jects  had  lost  their  previous  molecular  remission, 
with almost all relapses occurring within 6 months of 
drug cessation. However, 41% continued to maintain 
a molecular remission, resulting in a distinct “break” 
in the slope of the relapse-free survival curve (Fig. 1). 
All patients who relapsed responded to reintroduction 
of imatinib. Low Sokal score, male sex, and duration Initial treatment for patient with chronic phase CML
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of imatinib treatment were factors predictive of CMR 
maintenance  after  the  drug  was  withdrawn.  These 
data suggest that patients who are exposed to ima-
tinib for longer periods of time might be more likely 
to  maintain  CMR12  and  more  importantly,  at  least 
some patients with CML may actually be cured by 
imatinib.13
second-Line Agents for cML patients 
Who Fail Imatinib Therapy
In spite of the dramatic benefits for imatinib docu-
mented  in  the  IRIS  and  STIM  trials,  a  substantial 
minority of patients fail to benefit fully from this agent 
due to toxicity, lack of efficacy, or poor compliance. 
Approximately  6%  of  patients  on  the  IRIS  study 
stopped treatment due to imatinib toxicity by 8 years. 
Imatinib lacked sufficient efficacy in another 16%. 
And the STIM study demonstrates that most patients 
with CML are still not being cured. To overcome these 
limitations,  additional  TKIs  have  been  studied  in 
CML-CP patients resistant to standard-dose   imatinib. 
Agents with activity in this setting are likely to over-
come at least some degree of imatinib resistance and 
may be better for first-line therapy. Three such agents 
(dasatinib, nilotinib, and bosutinib) have been studied 
in phase II and phase III trials for either CP or accel-
erated/blast  phase  (AP/BP)  of  CML. These  agents 
have been the subject of multiple reviews, and the 
reader is referred to these sources for details.14–17 The 
salient features of each agent are presented in Table 
1. Nilotinib uses the same molecular scaffold as ima-
tinib, while dasatinib and bosutinib are structurally 
completely different.
The activity of dasatinib for both CP and AP/BP 
CML was documented in the series of START trials. 
The START-R study of subjects with CML-CP that 
had failed standard dose imatinib (400 mg daily) ran-
domized participants to high-dose imatinib (800 mg 
daily) or dasatinib (70 mg BID;18). At a minimum 
follow-up of two years, the MCyR rate for dasatinib 
vs. imatinib was 53% vs. 33% (P = 0.017). Similarly 
the CCyR rate was 44% vs. 18% (P = 0.0025) and 
the MMR rate was 29% vs. 12% (P = 0.028). The 
estimated  progression-free  survival  (PFS)  favored 
dasatinib as well, with the mean PFS not reached at 
30 months in the dasatinib arm, but a PFS of about 
3 months in the imatinib arm. Twenty-three percent 
of subjects in the dasatinib arm stopped treatment due 
to adverse events which were mostly drug-related.
Nilotinib has also been evaluated via a phase II trial 
in CML-CP subjects who were refractory or intoler-
ant of imatinib.19 The clinical activity of nilotinib was 
very similar to that seen with dasatinib. Thus, with a 
minimum follow-up of two years, the MCyR rate was 
59%, CCyR rate was 44%, and the MMR was 28%. 
PFS was not reached at 36 months. Nineteen percent 
of subjects went off treatment due to adverse events.
Bosutinib is a dual ABL1/SRC TKI, which, like 
nilotinib and dasatinib, is somewhat more potent than 
imatinib in vitro, and which retains activity against 
several imatinib-resistant ABL1 mutants. In prelimi-
nary data from the phase II portion of a phase I/II study 
investigating bosutinib in patients with CML-CP and 
who were resistant or intolerant to imatinib, 75 of 96 
evaluable patients (78%) achieved a complete hema-
tologic response (CHR), 47 of 106 (44%) achieved an 
MCyR, and 35 (33%) achieved a CCyR.20 A MMR was 
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Figure 1. Maintenance of complete molecular response after discontinu-
ing imatinib therapy. panel A: All subjects. panel B: Subjects with at least 
12 months of follow-up. reproduced from11 with permission.Shieh et al
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achieved in 27 of 85 patients (32%), of which 15 (18%) 
were complete molecular responses (CMR).
In  addition,  multiple  newer  approaches  are  in 
clinical or preclinical development for treatment of 
CML-CP resistant to available treatment. Such agents 
may  provide  advantages  for  selected  patients  (for 
review, see21,22). Some newer therapies involve com-
binations of imatinib or other single TKIs with agents 
targeting other signaling molecules or pathways. These 
may include inhibitors of downstream kinases,23,24 his-
tone deacetylase inhibitors,25 regulators of alternative 
splicing,26 HSP90 inhibitors,27 scaffold protein antag-
onists28 and inhibitors of downstream transcriptional 
factors,29,30 among others. Most single agent therapies 
may be considered kinase domain inhibitors of the 
BCR-ABL1 protein. An exception is the switch inhib-
itor DCC-2036 that binds to critical residues involved 
in switching the kinase between the active and inac-
tive conformations.31 These agents have shown activ-
ity with purified proteins or cell lines. Thus there are 
many agents that may eventually be incorporated at 
earlier stages in the CML treatment continuum.
second Line TKIs as First-Line 
Therapy
Agents approved for second-line use have now been 
tested  for  initial  therapy.  The  major  findings  are 
  summarized in Table 2.
Dasatinib
Following  the  demonstration  of  substantial  activity 
for  dasatinib  against  refractory/relapsed  CML-CP, 
this TKI has now been evaluated for first line ther-
apy.  An  initial  phase  II  trial  involved  62  patients 
with newly-diagnosed chronic phase CML.32 Among 
50 patients with at least 3 months of followup, the 
CCyR rate was 94% and the MMR rate reached 82% 
by 18 months. Responses were very rapid, with most 
CCyRs occurring by 6 months of treatment. Treat-
ment  was  well  tolerated.  Estimated  24-month  EFS 
was 88%. These encouraging results were followed 
by the phase III Dasatinib versus Imatinib in Newly 
Diagnosed  Chronic-Phase  Chronic  Myeloid  Leu-
kemia  (DASISION)  trial.33  Five  hundred  nineteen 
patients  with  newly  diagnosed  CML-CP  were  ran-
domly  assigned  to  receive  dasatinib  (100  mg  once 
daily) or imatinib (400 mg once daily). The primary 
endpoint was CCyR at 12 months. After a minimum 
follow-up of 12 months, the rate of CCyR observed on 
at least one assessment significantly favored dasatinib 
(83% vs. 72%, P = 0.001). The rate of MMR was also 
higher with dasatinib than with imatinib (46% vs. 28%,   
P , 0.0001). In addition, responses were achieved in 
a shorter time with dasatinib. The safety profiles of the 
two treatments were similar. Five percent of dasatinib-
treated subjects withdrew from treatment due to toxic-
ity, while 4% of   imatinib-treated patients did similarly. 
Table 1. Comparison of BCr-ABL1 TKIs approved or in phase III clinical trials for CML-Cp.
Agent spectrum of  
kinases inhibited  
at nanomolar  
concentration
BcR-ABL1  
binding site
Relative  
potency for  
BcR-ABL1 vs. 
imatinib
Toxicity ABcG2 
substrate
Imatinib BCr-ABL1, c-KIT,  
pDGFr, c-FMS
Inactive 1 Fatigue, edema,  
myalgia, cytopenias,  
hypophosphatemia
+
Dasatinib .100 kinases, incl.  
BCr-ABL1, pDGFr,  
c-KIT, SrC family,  
EpHA family, BTK,  
BMx, c-FMS,
Active,  
inactive
200–300 Fatigue, effusions,  
hypocalcemia,  
hypophosphatemia,  
increased lipase and  
amylase,  
immuno-suppression,  
cytopenias
+
Nilotinib BCr-ABL1, c-KIT,  
pDGFr, c-FMS
Inactive 10–30 Hyperbilirubinemia,  
fatigue, increased amylase  
and lipase, hypocalcemia,  
hypophosphatemia,  
cytopenias
+
Bosutinib ABL1, SrC family N/A 1–10 GI, fatigue, cytopenia −Initial treatment for patient with chronic phase CML
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Dasatinib  was  approved  for  first-line  treatment  of 
newly diagnosed patients CML-CP in October 2010.
An  additional  randomized  study  comparing 
standard  dose  imatinib  with  dasatinib  for  newly 
diagnosed CML-CP is the S0325 Intergroup Trial, 
carried  out  by  four  North  American  cooperative 
groups between December 2006 and February 2009. 
Initial results were recently presented.34 The primary 
endpoint was the frequency of .4 log reduction in 
BCR-ABL1  transcripts  at  12  months.  Molecular 
response at 12 months was deeper in the dasatinib 
arm (median 3.3 log reduction in BCR-ABL1 tran-
script vs. 2.8 with imatinib, P = 0.048) as was MMR 
(59% vs. 43%; P = 0.042); however, the propor-
tion achieving .4 log or .4.5 log reductions did 
not differ significantly. CCyR rate at 12 months, as 
well as PFS and overall survival were not differ-
ent between the two arms. A higher proportion of 
dasatinib-treated patients experienced grade 4 hema-
tologic  and  non-hematologic  toxicities.  Followup 
is continuing to determine if the deeper molecular 
response in the dasatinib-treated subjects will lead 
to improved long-term outcomes.
Nilotinib
Another  recent  randomized,  prospective  trial  has 
compared nilotinib with standard dose imatinib for 
initial therapy of CML-CP.35 In the phase III Eval-
uating  Nilotinib  Efficacy  and  Safety  in  Clinical 
Trials-Newly Diagnosed Patients (ENESTnd) trial, 
nilotinib at a dose of either 300 mg or 400 mg twice 
daily was compared with imatinib 400 mg once daily 
in patients with newly diagnosed CML in the chronic 
phase. The rate of MMR at 12 months was the pri-
mary end point. The MMR rate for nilotinib-treated 
subjects  was  significantly  better  than  for  imatinib 
patients (44% [300 mg/d] or 43% [400 mg/d] vs. 
22%; P = , 0.001). In addition, the rate of CCyR by 
12 months was significantly higher for nilotinb (80% 
for the 300 mg dose and 78% for the 400 mg dose) 
than for imatinib (65%; P , 0.001). The proportion 
of  patients  who  stopped  treatment  due  to  adverse 
events was similar in each treatment arm. In June 
2010, the FDA approved nilotinib for the treatment 
of adult patients with newly diagnosed Philadelphia 
chromosome  positive  chronic  myeloid  leukemia 
(Ph + CML) in chronic phase.
Table 2. Comparison of dasatinib, nilotinib, high-dose imatinib, and bosutinib as first-line treatment of CML-CP, in terms of 
response at 12 months, pFS, and toxicity.
Agent,  
schedule  
(vs. imatinib 
400 mg QD)
ccyR*  
(vs. imatinib  
400 mg QD)
MMR*  
(vs. imatinib 
400 mg QD)
pFs*  
(vs. imatinib  
400 mg QD)
comments Refs
Dasatinib  
100 mg QD
77% vs. 66% 46% vs. 28% 96% vs. 97%  
at 12 months (NS)
Higher incidence of pleural  
effusions in dasatinib arm.  
No difference between each  
arm in % of patients who DC’d  
drug because of AE.
33
Dasatinib  
100 mg QD
82% vs. 69%  
(NS)
59% vs. 43% 97% vs. 95%  
at 12 months (NS)
Only 51% of subjects had  
CCyr data available
34**
Nilotinib  
300 mg BID
80% vs. 65% 44% vs. 22% N/A Higher incidence of rash,  
increased bilirubin and  
AST/ALT in nilotinib arm.
35
Imatinib  
400 mg BID
64% vs. 58%  
(NS)
49% vs. 41% 
(NS)
86% vs.72%  
at 36 months (NS)
Median average daily dose  
720 mg daily
41
Imatinib  
400 mg BID
69.9% vs. 65.6% 
(NS)
46.4% vs.  
40.1% (NS)
97.4% vs. 95%  
at 18 months (NS)
Average daily dose 620 mg  
daily. 66.8% of patients had  
dose interruption .5 d vs. 37.6%.
40
Imatinib  
400 mg BID
62.9% vs. 49.4% 59% vs. 44% 94% vs. 94% at 
36 months (NS)
Only 16.7% of patients in  
high-dose treatment arm  
could tolerate full-dose.
39
Imatinib  
400 mg BID
47.8% vs. 37.3% 
(NS)
32.1% vs.  
25.4% (NS)
97.3% vs. 93.9%  
at 12 months (NS)
Only 54.4% of patients tolerated  
high-dose imatinib.
42
notes: *Values statistically significant unless otherwise noted. **Preliminary data.Shieh et al
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Bosutinib
This  new  SRC/ABL1  inhibitor  has  recently  com-
pleted accrual for the phase III randomized Bosutinib 
Efficacy  and  Safety  in  Chronic  Myeloid  Leuke-
mia (BELA) study, involving 502 newly diagnosed 
CML-CP. Subjects were assigned to bosutinib 500 mg 
or imatinib 400 mg daily with a primary endpoint of 
CCyR at 12 months. A preliminary report was pre-
sented as ASH 2010, and showed activity in CML-CP, 
as well as novel toxicities.36 Because of the lack of 
mature clinical data in peer-reviewed publications, 
bosutinib will not be discussed further in this review.
High-dose imatinib
An additional approach to enhancing first-line ther-
apy for CML-CP is to use higher doses of imatinib. 
Multiple studies have demonstrated that molecular or 
cytogenetic outcomes for CML-CP depend on dose 
intensity. Promising phase II studies suggested that 
high-dose imatinib therapy (600–800 mg daily) could 
have a higher and faster rate of meaningful responses 
than standard doses (400 mg daily). The GIMEMA 
CML  Working  Party  completed  the  first  prospec-
tive phase II trial to evaluate the efficacy and toler-
ability of high-dose imatinib in previously-untreated 
CML patients.37 Seventy-eight patients were treated 
with imatinib 400 mg twice daily. CCyR rates at 12   
and  24  months  were  88%  and  91%;  moreover,  at 
12 and 24 months 56% and 73% of CCyR patients 
achieved a MMR. For the same risk category, these 
response rates were faster than those documented in 
the IRIS trial. The Rationale and Insight for Gleevec 
High-Dose Therapy (RIGHT) trial also demonstrated 
similar promising results.38
Subsequently,  four  randomized,  prospective  trials 
evaluated  a  high-dose  imatinib  regimen  in  CML-CP. 
Using a dose escalation design, the German CML Study 
Group reported results comparing tolerability-adapted 
imatinib 800 mg/d versus 400 mg/d versus 400 mg/d 
plus inteferon-α, in newly-diagnosed CML patients.39 
Initial treatment in all study arms was imatinib 400 mg 
once daily. However, if no CHR was reached after two 
months or no MCyR was reached after six months, a 
dose increase was permitted. A significantly higher rate 
of MMR at 12 months occurred with tolerability-adapted 
imatinib 800 mg/d than with imatinib 400 mg/d (59% vs. 
44%, P , 0.001) or than with imatinib 400 mg/d plus 
IFN-α (59% vs. 46%, IP = 0.002). Three other studies 
have used a more traditional study format; none found 
an improvement in major endpoints with higher dose 
imatininb. Cortes et al. randomly assigned 476 newly-
diagnosed patients with CML in a 2:1 fashion to receive 
either high-dose or low-dose imatinib.40 Seventy percent 
of subjects had low Sokal scores. At 12 months, differ-
ences in MMR and CCyR rates were not statistically 
  significant. However, MMR and CCyR did occur faster at 
six months among patients assigned to imatinib 800 mg 
daily. Baccarani et al. have evaluated the use of high-dose 
imatinib as front-line treatment in high-risk CML-CP.41 
This European LeukemiaNet study compared imatinib 
400 mg daily to 800 mg daily in 216 newly diagnosed 
patients with CML and high Sokal scores. The CCyR at 
1 year was 58% and 64%, respectively, which was not 
statistically significant. There were no differences detect-
able in the cytogenetic response at three and six months, 
in the molecular response rate at any time, as well as in 
the rate of other events. Moreover, only 28% of patients 
in the high-dose arm could tolerate the full dose. Finally, 
the ISTAHIT study from the Central   European Leuke-
mia Study Group has reported insignificant increases in 
CCyR and MMR at 12 months, in patients treated with 
800 mg daily of imatinib, compared with those receiving 
400 mg daily.42 This study also noted faster responses 
with the higher dose, but only 45.6% of subjects could 
tolerate the 800 mg dose.
Treatment for newly Diagnosed 
cML-cp: are second-Line TKIs First 
in Line?
Randomized, prospective studies have failed to con-
firm an advantage for high-dose imatinib as first-line 
therapy in CML-CP. In addition, the phase III data for 
bosutinib are preliminary and mixed as to a poten-
tial benefit. Thus we will not consider these further 
as current treatments for CML-CP. However, we may 
consider that dasatinib and nilotinib may now be via-
ble alternatives to standard dose imatinib.
How can one decide among the alternative first-line 
therapies for CML in CP? Potential points to consider 
include the strength of the data supporting the approval of 
dasatinib and nilotinib as alternative first line   therapies. 
We will also want to review the drawbacks to standard 
dose imatinib therapy, including mechanisms for ima-
tinib resistance and toxicity. We will then examine if 
the newer agents offer a significant benefit in terms of 
avoiding these limitations to imatininb therapy.Initial treatment for patient with chronic phase CML
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Surrogate endpoints
For both dasatinib and nilotinib, the data favoring their 
use as first line therapies are based on surrogate end-
points and relatively short followup periods. Survival 
endpoints  have  not  been  reported  for  either  agent  in 
first-line use.33,35 Therapeutic studies of CML have con-
sistently used endpoints developed by the European Leu-
kemia Network and validated in multiple studies. Thus 
CCyR and MMR are recognized as surrogate endpoints 
that  predict  for  an  improvement  in  progression-free 
survival, a lower chance of loss-of-response, and less 
frequent  transformation  to  more  aggressive  disease. 
Interventions  which  achieve  improvements  in  these 
two parameters, compared to a standard therapy, are 
associated temporally with an improvement in over-
all survival of CML.7 However, early achievement of 
CCyR does not always translate into improvement at 
12 months in either CCyR or MMR.40,43 Thus, while 
some uncertainty exists as to the best time for assess-
ment of CCyR and MMR, the times used in the first-line, 
randomized trials of dasatinib and nilotinib are consis-
tent with proposed optimal values.44 The quality of the 
data for improved outcomes associated with early use 
of dasatinib or nilotinib generally supports their first-
line use. There are discrepancies between the DASI-
SION and S0325 trials of first-line dasatinib, though 
both use validated surrogate endpoints. Both report an 
improvement in MMR at 12 months. However DASI-
SION found a statistically significant improvement in 
CCyR at 12 months (P = 0.001 compared with ima-
tinib therapy) whereas thus far S0325 has not found 
such an effect (P = 0.097). One possible explanation 
for the difference is the fact that CCyR data were avail-
able for only 51% of the subjects in the S0325, possi-
bly impairing the power to detect differences.
Toxicity
Imatinib, dasatinib, and nilotinib are generally well 
tolerated.  Nevertheless  significant  toxicities  can 
occur  and  may  impact  compliance,  which  can  in 
turn impair treatment outcome (see below). In the 
phase III studies of first-line treatment of CML-CP 
using  dasatinib  or  nilotinib,  similar  proportions  of 
patients  stopped  treatment  due  to  adverse  events, 
regardless of the TKI. In the ENESTnd trial (nilo-
tinib vs. imatinib) the proportion of subjects stopping 
therapy due to AEs was 5% (nilotinib 300 mg/d), 9% 
(nilotinib 400 mg/d), and 7% (imatinib 400 mg/d).   
The DASISION trial (dasatinib vs. imatinib) docu-
mented that 5% of subjects receiving dasatinib stopped 
therapy due to AEs, whereas 4% of the imatinib-treated 
patients terminated treatment due to toxicity.
Common toxicities to all three TKIs include nausea, 
fatigue, and rashes. Rarely are these more than grade 
1–2, and they are unlikely to lead to drug interruption. 
Cytopenias are also common with all three agents. How-
ever, grade 3–4 cytopenias affect only about 10%–20% 
of patients, and the incidence does not differ among 
subjects treated with any of the drugs. All three agents 
also produce a variety of metabolic anomalies, particu-
larly hypophosphatemia or hypocalcemia. Concurrent 
use of bisphosphonates may exacerbate this problem. 
Unique toxicities of each TKI also are usually no more 
than grade 1 or 2 in severity. Nevertheless they could 
alter the choice of agent to use in specific patients.
Fluid retention
Fluid retention is a common side-effect with imatinib 
use. First-line dasatinib and nilotinib treatment are 
associated with lower rates of edema. However, pleu-
ral or pericardial effusions are a distinct side-  effect 
of dasatinib. Patients with pre-existing effusions or 
ascites from any cause are probably not optimal can-
didates for first-line dasatinib therapy, but if use of 
this  agent  is  necessary,  dose  limitations,  low-dose 
glucocorticoid therapy, or diuretics may be needed.
Bleeding
Dasatinib has been found to produce a platelet func-
tion defect due its inhibition of SRC-family kinases. 
The qualitative and quantitative effects of this coagu-
lopathy resemble those of aspirin.45 In leukemia trials 
involving dasatinib, major bleeding events were usu-
ally  associated  with  high-grade    thrombocytopenia. 
In addition there is a greater risk of bleeding with 
advanced stage of CML. In patients with CML-CP, 
gastrointestinal bleeding is uncommon. In one study 
the overall incidence was 5%, but grade 3 or greater 
hemorrhage  occurred  in  only  0.4%  of  subjects.46 
Dasatinib could be a less-attractive option for subjects 
with an ongoing coagulopathy, use of anti-  coagulants, 
or low platelet counts.
Cardiac toxicity
Both dasatinib and nilotinib have been associated with 
prolongation of the QT interval,47,48 whereas no similar Shieh et al
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concern exists for imatinib.46 In the case of nilotinib, 
this is associated with a “black box” warning on the 
prescribing information sheet. For both agents, cor-
rection of any associated hypokalemia or hypomag-
nesemia is mandated prior to TKI therapy. Treatment 
with either agent is not recommended for patients with 
congenital long QT syndrome, and it is discouraged 
for patients with obligate use of certain agents that 
can also prolong QT intervals, such as anti-arrhyth-
mia agents, azole anti-fungal agents, and quinolone 
antibiotics.
Gastrointestinal side-effects
Diarrhea is also fairly common with imatinib and can 
be  managed  with  antidiarrheal  medication.  Upper 
gastrointestinal  symptoms  such  as  heartburn  may 
be alleviated if taken with food and water. In con-
trast, nilotinib and dasatinib cause less gastrointesti-
nal side-effects, though nilotinib must be taken on an 
empty stomach because its absorption is altered with 
food. Dasatinib can be taken with or without food.
Nilotinib  has  a  disproportionate  incidence  of 
hyperbilirubinemia,  compared  with  dasatinib  and 
  imatinib. As many as 9%–15% of CML subjects in 
phase II nilotinib trials have been observed to have 
grade 3–4 hyperbilirubinemia. The elevation is pri-
marily unconjugated bilirubin, and may be associ-
ated with the UGT1 A1*28 polymorphism of a key 
enzyme in bilirubin conjugation.49 Since the impli-
cations of this anomaly are unknown, it would be 
best to avoid using nilotinib in subjects with a his-
tory of Gilbert’s syndrome or anomalies of bilirubin 
conjugation.
Both nilotinib and dasatinib can produce striking 
elevations of amylase and lipase, at times equivalent 
to grade 3 or 4 toxicity. Gastrointestinal symptoms are 
infrequent in these subjects, and anatomic or radio-
graphic abnormalities of the pancreas have not usually 
been  demonstrated.  The  abnormal  enzyme  patterns 
usually resolve during withdrawal of the TKI.
Immunosuppression
A potential toxicity of dasastinib is immunosuppres-
sion.  Many  activating  signals  for T  cells  involve 
SRC family kinases and BTK kinase, which can be 
inhibited at clinically achievable concentrations by 
dasatinib. Most studies of the effects of dasatinib 
on immune functioning have involved immortalized 
or  normal  primary  cells  treated  ex  vivo.  Various 
effects  have  been  described,  such  as  inhibition 
of TLR  signaling,  inhibition  of T  cell  activation, 
reduction in cytokine release from basophils, and 
suppression of Treg function.50–53 The results or rel-
evance of these potentially immunosuppressive and 
anti-inflammatory effects in vivo are not clear. One 
report describes an increased incidence of infections 
typically  seen  in  immunosuppressed  patients,  in 
12/16 subjects on dasatinib trials.54 Blood obtained 
from those subjects before and after dosing with dasa-
tinib was examined for activation of T cell and baso-
phil functions. These ex vivo experiments showed 
transient and erratic suppression of IgE-dependent 
activation  of  blood  basophils  and  TcR-dependent 
activation of   T-lymphocytes. During a recent clinical 
trial using dasatinib therapy for castration-resistant 
prostate cancer, we performed serial assays to detect 
evidence  of  drug-induced  immunosuppression.55 
Whole  blood  was  repeatedly  obtained  before  or 
2–3 hrs after dasatinib administration during several 
weeks of treatment.   Phytohemagglutinin (PHA) was 
added to the whole blood and incubated for 2 hrs. 
Messenger RNAs were then isolated by a previous-
ly-described  method,56  involving  plate  filtration, 
lysis, reverse transcription, and on-membrane ampli-
fication  via  RT-PCR  to  quantify  PHA-stimulated 
cytokine mRNAs. Results for a typical subject are 
shown in Figure 2. An immediate 1- or 2-log reduc-
tion in PHA-induced stimulation of GM-CSF, GZMB, 
CD40L and IL-2 expression was seen in this patient, 
and in all other evaluable subjects (n = 11). This 
suppressive effect of dasatinib on T cell functions 
persisted throughout the treatment period in most 
patients, but PHA stimulation of cytokine release 
returned to normal following the end of dasatinib 
therapy.  These  data  suggest  that  real  impairment 
of T cell function is a common feature of dasatinib 
therapy in cancer patients. Subjects who are already 
chronically immunosuppressed might be best treated 
with an alternative TKI.
Proinflammatory effects
While the immunosuppressive function of dasatinib has 
been described most often, there are also data to sug-
gest that dasatinib can also mediate a pro-  inflammatory 
effect. Pleural effusions in dasatinib-treated subjects 
characteristically  have  abundant  lymphocytes,  at Initial treatment for patient with chronic phase CML
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times associated with a peripheral blood lymphocy-
tosis as well.57 An increase in peripheral blood cyto-
toxic T cells has been described in some reports of 
dasatinib-treated patients.58 A pro-inflammatory effect 
by dasatinib may be responsible for reports of pannic-
ulitis in dasatinib-treated patients. Two female patients 
with  CML-CP  developed  severe  panniculitis  after 
exposure to dasatinib.59 In one patient, withdrawal and 
reintroduction of dasatinib together with prednisone 
successfully controlled the panniculitis. However, the 
rash did not respond to steroids in the second patient. 
Onset of lupus and rheumatoid arthritis has also been 
described during dasatinib therapy.54,60
Compliance
When deciding among imatinib, dasatinib, or nilotinib 
as the initial first-line therapy for a patient with CML, 
physicians  will  no  doubt  have  to  consider  patient 
adherence as well as cost. Cost will likely become 
more of an important health care issue when generic 
imatinib becomes possible in 2015.61
While formal clinical trials identify no significant 
differences among the three TKIs in terms of the per-
cent of patients who stop treatment due to adverse 
events, these data may not represent the situation in 
routine clinical care. Patients on trials are likely to 
be more highly motivated to comply with treatment. 
However,  during  routine  care,  toxicities  and  costs 
may become limiting. Patients who claim to be con-
tinuing treatment with imatinib may have suboptimal 
outcomes due to compliance issues. In the ADAGIO 
study, up to a third of subjects were considered to 
be non-compliant with the prescribed imatinib regi-
men, while only 14.2% of subjects were perfectly 
  compliant.62 Patients with a suboptimal response had 
significantly higher mean percentages of imatinib not 
taken (23.2%) than did those with optimal response 
(7.3%). Additionally, Marin et al.63 found a highly sig-
nificant correlation between the probability of major 
molecular response at 6 years, and the adherence rate 
(, or = 90% or . 90%) in subjects who had achieved 
a CCyR on imatinib therapy. Dose density has also 
been shown to significantly impair the achievement 
and maintenance of key cytological and molecular 
endpoints that predict for good outcomes.64 Because 
of the concern about poor compliance and underdos-
ing, some investigators are now advocating frequent 
monitoring of imatinib trough blood levels.65,66
Dasatinib  and  nilotinib  may  also  be  subject  to 
societal barriers to optimum use. A comparison of the 
total cost of therapy for dasatinib and nilotinib was 
recently presented.67 Patients treated with dasatinib 
experienced higher levels of healthcare resource uti-
lization and medical service costs, particularly related 
to  hospitalizations.  Dasatinib  patients  were  also 
observed to have more frequent ER visits and outpa-
tient visits compared to nilotinib patients, although 
the differences were not statistically   significant. Total 
medical service costs during the study period aver-
aged $18,477 for dasatinib patients and $6,571 for 
nilotinib patients, with an unadjusted cost difference 
of $11,905, which was statistically significant. Inter-
estingly, though nilotinib requires twice daily dosing 
and dasatinib is recommended as a once daily dose, 
the dasatinib cohort exhibited lower levels of treat-
ment adherence compared to the nilotinib cohort. One 
possible explanation for this finding may be related to 
the safety profiles of each drug, as adverse events can 
disrupt treatment.
Ghatnekar et al. recently reported on a study assess-
ing the cost-effectiveness of dasatinib versus high-
dose  imatinib  for  second-line  treatment  in  chronic 
phase CML patients, resistant to lower doses of ima-
tinib (#600 mg) in Sweden.68 A Markov simulation 
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Figure 2. Serial analysis of pHA-induced cytokine mrNA expression 
in a subject treated with dasatinib for prostate cancer. Solid circle: GM-
CSF mrNA; open diamond: IL-2 mrNA; solid triangle: GZMB mrNA; 
open square: CD40 L mrNA; open circle: ACTB mrNA. All values were 
  normalized to day 0 ACTB (= 1). Dasatinib (100 mg/d) was administered 
from day 1 to day 135.Shieh et al
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model  was  adapted  to  Swedish  treatment  practice. 
The model was populated with efficacy data from 
clinical trials, resource utilization by expert opinion, 
published quality of life data and unit prices from offi-
cial price lists. The results showed that chronic phase 
CML patients resistant to standard dose imatinib gain 
on average 0.67 life-years, or 0.62 quality adjusted 
life-years, when treated with dasatinib 140 mg daily 
compared with high-dose imatinib 800 mg daily. The 
incremental societal cost amounts to EUR 4250 dur-
ing the lifetime period, or EUR 6880 per quality-of-
life-year gained. In aggregate these data suggest that 
careful attention to patient motivation and insurance 
resources will be important in selecting among the 
possible TKIs for initial therapy.
BCr-ABL1 mutations
Resistance  to  imatinib  and  other  TKI  treatment  is 
mediated through a variety of mechanisms, including 
BCR-ABL1  mutations  affecting  the  kinase  domain, 
BCR-ABL1  amplification  and  overexpression,  the 
activation  of  alternative  resistance  pathways  in  the 
leukemic  clone,  and  expression  of  drug  resistance 
proteins.  These  mechanisms  have  been  the  subjects 
of many recent reviews, and the reader is referred to 
these sources for details.21,69,70,71,72 In addition, pharma-
cokinetic/pharmacodynamic effects may result in lower 
trough levels of imatinib and poorer   outcomes.65 Quan-
titatively, mutations in the BCR-ABL1 chimeric gene 
account for the greatest fraction of identified resistance 
mechanisms. More than 50 or more mutations in the 
BCR-ABL1 sequence have been cataloged, primarily 
point mutations but also including frame shift mutations 
due to insertions or deletions.73,74 Attention has focused 
most closely on those in the kinase domain, particularly 
the P-loop.75
De novo BCr-ABL1 mutations
Imatinib, dasatinib, and nilotinib differ substantially in 
terms of the spectrum of mutant BCR-ABL1 sequences 
that they inhibit, and also in terms of the mutations 
that arise during therapy with the individual TKIs. It 
might be surmised that the presence of aberrant BCR-
ABL1 genotypes could profoundly affect the choice 
of initial therapy, but it is not clear that this is the case. 
Polymorphisms in the BCR-ABL1 sequence may be 
present at the point of diagnosis, before any therapy 
has been administered. These may be known “normal” 
polymorphisms in the BCR or ABL1 sequences, or 
may be non-functional or functional mutations that 
can affect the kinase activity of the enzyme. The tra-
ditional view has been that these mutations, including 
the multi-drug resistant T315I allele, may be present 
at diagnosis but seldom cause imatinib resistance.76,77 
Because of the infrequent finding of pre-treatment 
mutations,  the  inconsistency  in  predicting  disease 
course, and the generally successful outcome from 
first-line imatinib therapy, the routine search for BCR-
ABL1 polymorphisms at the time of diagnosis is not 
recommended.78,79,80    However,  a  recent  report  has 
identified a high frequency (61.5%) of pre-treatment 
BCR-ABL1 mutations involving the kinase domain 
among  patients  with  a  high  Sokal  score,  whereas 
patients with a low Sokal score were mutation-free.81 
The  mutations  frequently  involved  the  P-loop  and 
would be predicted to confer resistance to imatinib, 
and possibly nilotinib. Several of these patients failed 
initial and salvage TKI therapy and died. If confirmed 
by larger studies, the presence of pre-treatment muta-
tions in CML-CP cells could inform the decision as to 
initial treatment.
Acquired BCr-ABL1 mutations
Most resistance mutations in the BCR-ABL1 kinase 
emerge during TKI therapy. If the three TKIs differed 
in their ability to suppress the emergence of mutant 
kinases, one could use this as a basis for preference. 
Extensive studies have been made of the spectrum of 
polymorphisms that emerge during imatinib therapy 
(for reviews, see75,82,83). “Hot spots” for mutations dur-
ing imatinib therapy include the P-loop, the catalytic 
domain, the activating loop, and the T315 gatekeeper 
locus. Few data exist to describe mutations that arise 
during dasatinib or nilotinib therapy, and then only 
in the setting of second-line treatment.84 Most of the 
dasatinib-associated mutations appear to be polymor-
phisms that do not directly confer dasatinib   resistance. 
Known dasatinib-resistance mutations such as F317L 
and T315I appear to be a distinct minority. No reports 
have yet described the emergence of mutations during 
first line therapy with dasatinib or nilotinib. However, 
cross-resistance  among  possible  mutants  appears 
unlikely.  P-loop  mutants  appear  to  be  resistant  to 
nilotinib  and  imatinib,  but  sensitive  to  dasatinib. 
Conversely, nilotinib seems to be more active against 
F317L than does dasatinib.71,85,86 The T315I mutation Initial treatment for patient with chronic phase CML
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is highly resistant to all three TKIs, but fortunately 
only represents about 15% of all clinically-detected 
BCR-ABL1 mutations.
Tailoring therapy based on BCr-ABL1 
mutations
Insight into the potential for the 3 TKIs to suppress the 
emergence of specific mutations can be found in the 
studies of Bradeen, et al.87 These investigators used 
an ENU mutagenesis strategy to treat murine lym-
phoblasts containing the p210 BCR-ABL1 protein. 
Selection of mutants was performed in the presence 
of various concentrations of imatinib, dasatinib, or 
nilotinib. The 26 recovered mutants represented 83% 
of  the  then-known  clinical  BCR-ABL1  mutations, 
demonstrating that the model faithfully reproduces 
the  natural  history  of  BCR-ABL1  mutations  seen 
clinically. Mutations arose in wells treated with all 
three TKIs. The pan-resistant T315I mutation arose 
in the presence of any of the three inhibitors. P-loop 
mutations arose in the presence of either imatinib or 
nilotinib,  but  not  dasatinib.  Conversely  the  F317L 
mutation  (and  other  F317  polymorphisms)  associ-
ated with dasatinib resistance appeared only in the 
presence of that TKI. It remained sensitive to nilo-
tinib and imatinib. Dasatinib selection was associated 
with the lowest total number of mutations, with nilo-
tinib selection producing the next lowest. Imatininb 
therapy was associated with the greatest number and 
diversity of mutations, but almost all remained sen-
sitive to the alternative TKIs. Combination therapy 
(dasatinib plus nilotinib, or dasatinib plus imatinib) 
eliminated the development of essentially all BCR-
ABL1 mutations except T315I.
With the exception of T315I, do any of the described 
resistance-associated mutations make a practical dif-
ference to initial therapy? A recent mathematical anal-
ysis has examined the probability of treatment success 
based on the number of cross-resistant mutants in the 
Bradeen data.88 The model postulates the existence of 
variant BCR-ABL1 kinases that are resistant to one, 
two, or three TKIs (such as imatinib, dasatinib, and 
nilotinib).  In  general,  the  mutations  which  confer 
resistance to the largest number of drugs in the com-
bination are the ones which define how likely it is 
that the protocol fails. Based on this premise, Katouli 
and Komarova developed a counting strategy which 
can  weigh  different  treatment  strategies  according 
to  their  cross-resistance  properties,  and  find  the 
protocols with the highest probability of treatment 
success.88 In developing their algorithm, the authors 
constructed a data set allowing the determination of 
the number of possible resistant and cross-resistant 
mutants in the context of combing drugs and different 
  concentrations. Notably, any single- or double-resis-
tant mutation is ultimately manageable by the sequen-
tial or combined use of inhibitors. The initial choice of 
treatment is claimed to be less important because the 
limited cross resistance will not prevent ultimate suc-
cess. At low (5 nm) and medium (10–25 nm) concen-
trations of dasatinib, certain mutations arose (F317C, 
F317V, V299L) that did not also confer resistance to 
imatinib or nilotinib, suggesting that dasatinib could 
be used as first-line therapy, with imatinib or nilotinib 
used later if necessary. An alternative view based on 
empiric, clinical data suggests that a more cautious 
approach is necessary. Mutations can arise rapidly 
during TKI therapy,89 and second-line treatments are 
not nearly as effective as first line therapy when resis-
tance is clinically apparent. Optimal first-line single 
(or combination) TKI therapy may be preferable to 
reliance on a sequential approach.
resistance of CML stem cells  
to imatinib
CML persistence and relapse is associated with the 
presence of leukemia stem cells which are protected 
from the adverse effects of therapy. It has been specu-
lated that a pool of CML stem cells may persist in a 
dormant state as a residual, resistant population, with 
the ability to repopulate the leukemic clone, even in 
patients who are in CMR.82 CML stem cells are widely 
viewed as being resistant to BCR-ABL1 inhibition.90,91 
The recent observation from the STIM trial of a dis-
tinct “break” in the relapse-free survival curve after 
imatinib withdrawal suggests that sometimes imatinib 
therapy may be associated with clonal extinction of 
the leukemic stem cells. But in most cases resistance 
is the rule both in the laboratory and the clinic. The 
causes  for  this  resistance  are  controversial  and  are 
usually  attributed  to  the  effects  of  growth  factors, 
stromal  signals,  and  alternative  intracellular  signal-
ing  mechanisms.  Nilotinib92  and  dasatinib93  have 
also been evaluated for their ability to inhibit primi-
tive CML cells. Dasatinib has been of special inter-
est due to its ability to inhibit multiple other kinases, Shieh et al
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  including  SRC    family  members.  Dasatinib  targets 
an earlier   progenitor   population than imatinib and is 
likely more effective than imatinib within the stem 
cell  niche.93  Under  some  culture  conditions  dasat-
inib can suppress growth of CML long-term culture 
initiating cells more than does imatinib, at clinically 
achievable  doses.94 However, it does not appear to 
induce apoptosis or clonal extinction more than does 
imatinib. To improve on the intriguing results docu-
mented in the STIM trial, it is likely that combinations 
of TKIs (including non-BCR-ABL1-targeting agents) 
or combinations of a BCR-ABL1-targeted TKI with 
conventional cytotoxic agents will be needed.
conclusions
Today, patients newly-diagnosed with CML-CP have 
more options when starting TKI therapy. Inevitably for 
physicians, with more options come more questions on 
how to choose the right TKI for each individual patient. 
Will it be standard imatinib, dasatinib, or nilotinib? The 
answer will depend on factors such as toxicities, compli-
ance, cost, BCR-ABL1 mutation status, and the likeli-
hood of being able to reach certain surrogate   endpoints. 
It is likely that there is no universal answer.
Dasatinib demonstrates improved outcomes in sur-
rogate markers for the most mature studies, compared 
with imatinib. Dasatinib may be especially attractive 
for patients with high Sokal scores, who are at risk for 
having pretreatment BCR-ABL1  mutations involv-
ing the P-loop. Preclinical models also suggest that 
dasatinib has the lowest rate of mutations developing 
during TKI therapy. However, toxicity and compli-
ance may be problematic, especially in patients with 
  co-morbidities and who take multiple medicines.
Nilotinib  also  has  improved  outcomes  in  surro-
gate markers compared with imatinib. Compared with 
  dasatinib-treated patients, subjects receiving nilotinib may 
have less costs and improved compliance. However the 
relatively common P-loop mutations in BCR-ABL1 may 
limit its usefulness as a first- or second-line agent. As 
with dasatinib, toxicity may be an issue in patients with 
  co-morbidities and who are on multiple drugs.
Imatinib  is  the  only  agent  for  which  improved 
overall survival has been documented. Furthermore, 
the STIM trial suggests that with selected patients 
(male,  low  Sokal  score)  it  remains  a  viable  (and 
possibly curative) option for long-term treatment of 
CML-CP.  If  a  generic  version  becomes  available, 
imatinib  treatment  may  result  in  significant  cost 
savings  compared  with  other TKIs.  Like  dasatinib 
and nilotinib, imatinib therapy also may be compli-
cated by poor compliance.
Each of the available agents has advantages and 
disadvantages, and only further randomized trials can 
provide definitive answers. It is likely that the next 
few  years  will  bring  new  studies  on  combination 
TKI therapy involving BCR-ABL1-targeting agents 
combined with other kinase inhibitors,95 or with che-
motherapy agents.96 In the meantime patients with 
CML-CP can be assured that there are already several 
excellent options for controlling their disease.
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